Kamada (NASDAQ:KMDA - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $11.00 price target on the biotechnology company's stock. HC Wainwright's price objective suggests a potential upside of 55.37% from the stock's current price. HC Wainwright also issued estimates for Kamada's Q1 2025 earnings at $0.07 EPS, Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.11 EPS and FY2029 earnings at $0.80 EPS.
Kamada Stock Down 4.5 %
Shares of NASDAQ KMDA traded down $0.33 during trading on Thursday, hitting $7.08. The company had a trading volume of 188,701 shares, compared to its average volume of 262,664. The firm has a market capitalization of $406.96 million, a price-to-earnings ratio of 25.29, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.15. The stock has a fifty day simple moving average of $7.13 and a two-hundred day simple moving average of $6.17.
Institutional Investors Weigh In On Kamada
Several hedge funds and other institutional investors have recently bought and sold shares of KMDA. JPMorgan Chase & Co. acquired a new stake in shares of Kamada during the 4th quarter worth about $67,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Kamada in the 3rd quarter valued at approximately $77,000. Plato Investment Management Ltd acquired a new position in shares of Kamada in the 3rd quarter worth approximately $117,000. NewEdge Advisors LLC boosted its position in shares of Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after purchasing an additional 8,260 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after purchasing an additional 1,549 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.
Kamada Company Profile
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Featured Articles
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
